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Abstract
The central nervous system (CNS) is an immune‐privileged tissue protected by the brain–
blood barrier (BBB), which limits the absorption of substances and cells from blood flow.
In the case of inflammatory diseases in the CNS, such as multiple sclerosis (MS), however,
autoreactive T cells that attack brain autoantigens, including myelin proteins, circum‐
vent the BBB. Despite the wide distribution of brain autoantigens, demyelination often
occurs as discrete foci. This fact suggests that there might be a certain cue that guides
autoreactive T cells to particular site(s) in the CNS. In other words, there exists a mechanism
that facilitates a site‐specific accumulation of autoreactive T cells in the CNS. Using a
murine model of MS, experimental autoimmune encephalomyelitis (EAE), we identi‐
fied dorsal vessels of the fifth lumbar (L5) spinal cord as the initial entry site of immune
cells. The formation of a gateway for immune cells is defined by local neural stimula‐
tions. For example, neural stimulation by gravity creates this gateway by increasing the
expression of chemokines that attract autoreactive T cells. Regional neural activation by
the other stimuli, such as electric pulses or pain sensation, also induces gateway formation,
but at different blood vessels via chemokine expression. These neuro‐immune interac‐
tions are examples of the gateway reflex and are extensively reviewed in this chapter.
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1. Introduction
Multiple sclerosis (MS) is a common neurological disease that is estimated to inflict more than
2.5 million patients worldwide [1–4]. MS is associated with chronic inflammation of the central
nervous system (CNS) with myelin antigens as the immune target during the inflammation
processes. The clinical manifestations of MS are variable and often include both symptoms of
upper motor neurons, such as hyperreflexia, ataxia, spasticity, and visual defects, and lower
motor neuron symptoms, such as sensory neuron defects and paralysis [5]. Given the uniform
presence of myelin antigens in the CNS, however, variable local, rather than systemic clinical
symptoms raise the possibility that there exists specific sites in the CNS that are vulnerable to
immune cells thus triggering auto‐reactivity. As discussed below, we observed using a murine
model  of  MS,  experimental  autoimmune  encephalomyelitis  (EAE),  that  regional  neural
stimulations permit entry of immune cells into the CNS, which may explain the variable MS
symptoms among patients.
Genetic susceptibility of MS is well studied, and major histocompatibility complex (MHC)
genes and genes associated with CD4+ helper T‐cell activation and homeostasis are
identified as susceptible genes. The strongest genetic linkage was found at certain alleles of
MHC class II, which suggests a relationship between autoreactive CD4+ T cells and MS
development in humans [6]. Consistently, autoreactive CD4+ T cells have important roles in
the development and relapse of animal models of MS [4, 7–13]. In addition to MHC genes,
several genome‐wide association studies (GWAS) of MS patients have identified addition‐
al genetic loci including interleukin (IL)‐17, IL‐2 receptor (CD25), and IL‐7 receptor (CD127),
which are important for CD4+ T‐cell effector function, activation, and survival [14–16]. These
lines of genetic evidence suggest that blocking CD4+ T‐cell entry into the CNS, thereby
blocking subsequent inflammation in the CNS, would be an effective way for the treat‐
ment of MS. Indeed, drugs that target T‐cell migration such as fingolimod (FTY720) and
natalizumab (anti‐VLA4 antibody) have shown clinical success in the treatment of MS.
Fingolimod is an orally available sphingosine‐1‐phosphate receptor modulator, which
reduces CD4+ T‐cell invasion to the CNS due to the inhibition of lymphocyte egress from
lymph nodes [17]. Natalizumab, on the other hand, targets alpha4 integrin (a subunit of
VLA4), which is required for the migration of CD4+ T cells to inflamed CNS [4, 18]. The
prominent clinical effects of these drugs provide a proof of concept for therapeutic strat‐
egies to suppress the invasion of autoreactive CD4+ T cells into the CNS. Because side effects
such as progressive multifocal leukoencephalopathy warrant caution for the use of fingoli‐
mod and natalizumab [19, 20], a novel strategy including a blockade of the entry site, or
gateway, of immune cells to the CNS is desired.
It is widely known that the CNS is an immune‐privileged site, protected by the blood–
brain barrier (BBB), which restricts the exchange of substances and cell migration into and
out of the organ. However, CNS invasion by immune cells occurs in not only neuropatho‐
logic conditions including MS, but also normal healthy conditions. We have been studying
where and how immune cells can enter the CNS using EAE models. In this chapter, our
Trending Topics in Multiple Sclerosis32
recent findings about these gateways, a mechanism to operate them, and perspectives are
discussed.
2. Blood–brain barrier and inflammation
The BBB is a specialized blood vessel formed by several cell types including vascular endo‐
thelial cells, pericytes, and astrocyte endfeet. In addition, tight junctions are critical for barrier
development and are established through interactions of tight junction molecules, such as ZO‐
1, claudins, and occludins, between the vascular endothelial cells to cause a size exclusion of
about 500 daltons [21, 22]. Despite this rigid barrier system, autoreactive T cells can enter to
the CNS and cause autoimmune diseases such as MS. The breakdown of the BBB is also
observed in neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease
[23]. Because neuroinflammation is associated with almost all diseases in the CNS [24], the
relationship between a dysfunctional BBB and inflammatory cytokines has been well studied.
For example, TNFαincreases BBB permeability during sepsis, and IL‐1β regulates the BBB via
reactivation of the HIF‐VEGF axis in MS [25, 26]. IFNγ and TNFα decrease the expression of
TWIK‐related potassium channel‐1 in human brain microvascular endothelial cells, which
leads to increase the transmigration of various immune cells across the endothelial cells in vitro
[27]. IL‐17A, which is a signature cytokine of Th17 cells, also contributes to BBB leakage in
vitro and in vivo. EAE was significantly suppressed in IL‐17A‐deficient mice [28], and IL‐17A‐
deficient CD4+ T cells hardly invade the CNS through the fifth lumbar (L5) spinal cord unlike
normal ones [12]. IL‐17A‐mediated BBB dysfunction involves the formation of reactive oxygen
species by cellular oxidases, which down‐regulate tight junction molecules and the activation
of the endothelial contractile machinery in vitro [29, 30]. Seeing that GWAS and animal model
data have revealed that autoreactive CD4+ T cells producing many cytokines play a central
role in MS, understanding the in vivo behavior of disease‐causing CD4+ T cells offers crucial
insights about the pathophysiology of MS. Intravital two‐photon imaging using a rat transfer
EAE model showed that there are at least three stages for CNS invasion by autoreactive CD4+
T cells: intraluminal scanning, perivascular scanning, and CNS‐surface scanning [31]. This
study also suggested that the reactivation of CNS‐invading CD4+ T cells by perivascular/
meningeal antigen‐presenting cells is followed by parenchymal infiltration of pathogenic
CD4+ T cells [31]. Chemokine guidance and cellular adhesion events of pathogenic CD4+ T
cells are also critical for the CNS invasion [12, 31]. Myelin autoantigen candidates associated
with MS including Myelin Basic Protein (MBP), myelin‐oligodendrocyte protein (MOG) and
proteolipid proteins (PLP) [32–35] are present throughout CNS white matter, while MS lesions
are often observed by MRI as focal plaques [36]. These facts suggest that there exists an
additional signal that directs pathogenic CD4+ T cells to initiate inflammatory reactions at
particular region(s) of the CNS. We recently demonstrated that this signal is provided by
several types of neural activations. We also defined a molecular mechanism of the resulting
neuro‐immune interactions for the development and relapse of murine models of MS, as
discussed in the following sections.
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3. Gravity‐mediated gateway reflex
We first considered the initial site where the autoreactive CD4+ T cells invade the CNS. In
EAE models, mice or rats are generally immunized with various CNS antigens such as mye‐
lin‐oligodendrocyte protein (MOG) emulsified with complete Freund's adjuvant (CFA) in
the presence of pertussis toxin administration, which are critical for the generation of autor‐
eactive CD4+ T cells and the induction of MS‐like symptoms, including a progressive para‐
lysis that usually begins at the tip of the tail. EAE can also be induced in wild‐type animals
by the transfer of autoreactive CD4+ T cells isolated from other EAE mice. This transfer EAE
model is induced without antigens, CFA, or pertussis toxin treatment, making this model
suitable for investigating the behavior of the disease‐causing CD4+ T cells in detail. Whole‐
mount sagittal sections of adult mice at a preclinical stage of the transfer EAE model (day 4
or 5 after MOG‐reactive CD4+ T‐cell transfer) revealed that MOG‐reactive pathogenic CD4+
T cells preferentially accumulated at the L5 spinal cord, but not in the brain at this early
stage. This observation suitably explains the first clinical symptom of typical EAE, a weak‐
ness of the tail tip. A closer analysis of the L5 spinal cord revealed that the accumulation of
MOG‐reactive CD4+ T cells occurred around the dorsal vessels. Various chemokines includ‐
ing Th17‐attracting CCL20 were up‐regulated at the L5 dorsal vessels during EAE compared
with dorsal vessels from other spinal cords. Indeed, anti‐CCL20 antibody treatment or trans‐
fer of MOG‐reactive CD4+ T cells lacking its receptor, CCR6, compromised the L5 accumula‐
tion of these CD4+ T cells and subsequent development of EAE, which is consistent with a
published study [37]. Interestingly, the selective up‐regulation of chemokines at the L5 dor‐
sal vessels was observed even at steady state, albeit to a lesser degree than in the EAE condi‐
tion. These results suggested that the L5 dorsal vessels are the first gateway for pathogenic
CD4+ T cells in this transfer EAE system (Figure 1), and some physiological effects under
steady state that modulate chemokine levels at the L5 dorsal vessels are enhanced during
EAE.
Further investigation revealed that the selective up‐regulation of chemokines at the L5 dorsal
vessels at steady state were the result of neuro‐immune interactions. It is known that neurons
in the dorsal root ganglion (DRG) beside the L5 spinal cord are connected to the soleus muscles,
the main anti‐gravity muscles [38]. Consistent with a constant stimulation of the soleus muscles
by Earth's gravity, the L5 DRG is the largest among all DRGs in mice and humans [39]. We
hypothesized that constant stimulation by gravity might mediate the uniqueness of the L5
spinal cord in establishing the gateway of immune cells including autoreactive CD4+ T cells.
Consistent with this hypothesis, we found two peaks of CCL20 expression at the dorsal vessels
of the cervical and lumbar cords, although CCL20 expression was higher at the latter. To
examine the effect of gravity, mice were suspended by their tails so that their hind legs were
released from gravity. This treatment resulted in a reduced accumulation of MOG‐specific
CD4+ T cells at the L5 cord. Instead, these CD4+ T cells invaded the cervical cords as if a new
gateway was created by the additional gravitational burden on the forefeet muscles due to the
tail suspension [12]. Consistently, the tail suspension downregulated CCL20 levels in the L5
dorsal blood vessels, but up‐regulated CCL20 in the cervical cords. Moreover, electric stimu‐
lations to the soleus muscles in tail‐suspended mice restored CCL20 levels and CD4+ T‐cell
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accumulation at the L5 spinal cord [12]. These results suggest that a certain neural activation
triggered by gravity contributes to the gateway at the L5 dorsal blood vessels for autoreactive
CD4+ T cells to infiltrate the CNS (Figure 1).
Figure 1. Gravity‐mediated gateway reflex. Constant gravity‐mediated stimulation of the soleus muscles induces the
activation of sensory nerves, whose cell bodies are located at the dorsal root ganglion (DRG) of the fifth lumbar (L5)
spinal cord. Signals via L5 DRG neurons travel to sympathetic neurons located nearby, resulting in norepinephrine
(NE) secretion at the dorsal vessels there. NE enhances the inflammation amplifier (Amp) in the L5 dorsal vessel endo‐
thelium, causing an up‐regulation of CCL20 and subsequent accumulation of pathogenic CD4+ T cells.
Sympathetic nerve activation was involved in the gravity‐mediated chemokine expressions at
the L5 dorsal vessels. c‐Fos expression, which is a marker of neural activation, was higher in
L5 sympathetic ganglions than in L1 sympathetic ganglions. Blood flow speeds at the L5 dorsal
vessels, but not at other blood vessels including L1 dorsal vessels, femoral artery, and portal
vein, became slower when mice were tail suspended, while electronic stimulation of the soleus
muscles increased the flow speed, suggesting an involvement of autonomic nerves including
sympathetic ones in this response [12]. Furthermore, pharmacological blockade of adrenergic
receptors significantly inhibited CCL20 levels, NF‐κB activation and MOG‐reactive pathogenic
CD4+ T‐cell accumulation at the L5 dorsal vessels, and also suppressed clinical signs of EAE
[12]. Thus, sensory nerve activation due to anti‐gravity responses leads to a sympathetic nerve
stimulation that creates a gateway for immune cells to pass through the CNS via the L5 dorsal
vessels [12]. This neuro‐immune response, which leads to change in the status of the vascular
endothelium, is named the “gateway reflex” [40–42]. Other examples of the gateway reflex are
described below.
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4. Electric stimulation‐mediated gateway reflex
Neural activations can be artificially induced by various methods including electric stimula‐
tions and treatment with reagents. We wondered if electric stimulation of different muscles
could create gateways in blood vessels at distinct positions via regional neural activations. As
discussed earlier, weak electric stimulation to the soleus muscles restored chemokine expres‐
sion at the L5 dorsal vessels of tail‐suspended mice, because the cell body of sensory neurons
in the soleus muscles is mainly located in the L5 DRG. We applied this methodology to other
muscles. As expected, electric stimulations to thigh muscles including the quadriceps, which
are known to be regulated by L3 DRG neurons, led to an increased expression of chemokines
in L3 dorsal vessels in mice, while electric stimulations of upper regions, such as forefoot
muscles including the epitrochlearis and triceps brachii, resulted in an up‐regulation of
chemokines in the fifth cervical to fifth thoracic cord dorsal vessels, which is where the DRG
Figure 2. Electric stimulation‐mediated gateway reflex. Artificially induced neural activation by weak electric stimula‐
tion followed by sensory‐sympathetic cross talk can trigger the gateway reflex. Electric pulses to the triceps induce
chemokine up‐regulation at the dorsal vessels of the fifth cervical (C5) to fifth thoracic (T5) spinal cord through activa‐
tion of the inflammation amplifier (Amp). Similarly, stimulation of the quadriceps induces a gateway at the dorsal ves‐
sels of the third lumbar (L3) cord, whereas the gateway dorsal vessels of the L5 cord are created by electric pulses to
the soleus muscles.
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neurons of the C5‐T5 spinal cords project to/from these muscles. These results established the
electric stimulation‐mediated gateway as another example of the gateway reflex (Figure 2). In
addition, they offer an important implication that the gateway reflex can be controlled by
artificially stimulating specific neurons, providing a promising opportunity for a novel
therapeutic strategy against inflammatory diseases in the CNS.
5. Pain‐mediated gateway reflex
It is reported that many MS patients experience pain, and some patients take pain relief
medication to improve their quality of life [43]. Pain is a common symptom in many diseases
and disorders, but it is often considered a symptomatic effect that arises from tissue damage
caused by the disease. However, it is known that pain triggers neural inputs via sensory
neurons expressing nociceptors such as TRPV1 [44, 45]. Therefore, we assumed that a pain‐
mediated gateway reflex might exist, which would affect the disease status of MS and EAE.
In EAE, modulations of nociception (pain sensation) are reported during the disease devel‐
opment [46]. Adoptive transfer of MOG reactive, pathogenic CD4+ T cells induces a transient
EAE within a week after transfer, followed by a remission phase. Mice that experienced the
first episode of EAE and are in the remission phase, which we termed EAE‐recovered mice,
never develop EAE symptoms again under normal conditions. We experimentally induced
pain sensation in these EAE‐recovered mice by ligating the middle branch of the trigeminal
nerves, which has been reported as being composed of only sensory neurons [47]. Pain
induction at the time of pathogenic T‐cell transfer resulted in a persistence of EAE symptoms
and caused considerable delay of the remission phase. On the contrary, suppressing pain by
medication inhibited EAE development in several mouse models including an active immu‐
nization model in SJL mice. Because a majority of MS progresses with relapse and it is reported
that pain is more intense in MS patients with higher disease scores [48], we examined whether
pain induction triggers EAE relapse in mice. EAE‐recovered mice were subjected to trigeminal
nerve ligation to induce pain sensation. In separate experiments, pain‐processing nerves were
also chemically activated by the injection of capsaicin and substance P at the cheek or forefeet
of EAE‐recovered mice. All these treatments induced relapse of EAE, indicating that pain is
not a simple by‐product of the disease, but significantly contributes to the development and
EAE relapse [13]. Similar to the gravity‐mediated gateway reflex, a sensory‐sympathetic
pathway is involved in the pain‐mediated EAE relapse, because pharmacological or genetic
inhibition of pain‐processing molecules such as TRPV1 and Nav1.8, and chemical ablation of
sympathetic neurons by 6‐hydroxydopamine (6‐OHDA) suppressed EAE relapse induced by
trigeminal nerve ligation. Interestingly, stress‐mediated events, including immobilization
stress and forced swimming stress (about 20 minutes/day), did not trigger EAE relapse
although serum corticosterone, norepinephrine, and epinephrine were induced at a similar
level to pain induction, suggesting that specific sensory‐sympathetic nerve pathways, rather
than systemic hormonal stress responses, mediate the relapse of EAE (Figure 3).
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Figure 3. Pain‐mediated gateway reflex. Pain‐induced sensory neuron activation results in the activation of specific
sympathetic neurons that control norepinephrine (NE) expression around the ventral vessels of every level of the spi‐
nal cords. This system is regulated by the anterior cinculate cortex (ACC) in the brain. Because the fifth lumbar (L5)
spinal cord abundantly contains MHC class II high activated monocytes, this region is affected significantly during
pain sensation. NE from pain‐specific sympathetic neurons at the ventral vessels induces the production of CX3CL1
from the activated monocytes, further recruiting these cells in an auto/paracrine manner. The MHC class II high acti‐
vated monocytes are able to present MOG antigens to pathogenic CD4+ T cells, which in turn activate the inflamma‐
tion amplifier (Amp) in regional endothelial cells and subsequently cause a relapse in the disease.
During the first episode of EAE, MOG‐reactive CD4+ T cells enter the CNS from the dorsal
vessels of the L5 spinal cord [12]. The transferred CD4+ T cells are then found at the upper
levels of the spinal cord and brain, which matches typical clinical manifestations of EAE
including the initial tail tip weakness and subsequent ascending paralysis. Intriguingly, after
pain induction in apparently normal EAE‐recovered mice, the relapse also starts from the loss
of tonicity of the tail tip, suggesting that the L5 cord could again be a gateway for relapse.
However, an immunohistochemical examination of the L5 spinal cord from EAE‐recovered
mice showed differences with naïve mice, with many MHC class II high monocytes around
the meningeal region. After pain induction, these cells accumulated at the L5 ventral vessels,
but not dorsal vessels within a day. This accumulation is dependent on a chemokine CX3CL1,
which is secreted from the MHC class II high monocytes themselves and astrocytes after
norepinephrine stimulation. Therefore, the pain‐mediated gateway reflex induces norepi‐
nephrine secretion from sympathetic neurons around the L5 ventral vessels and subsequent
auto/paracrine induction of CX3CL1 followed by MHC class II high monocyte accumulations.
Because these monocytes are able to present MOG peptides, circulating MOG‐reactive
pathogenic CD4+ T cells can recognize the L5 ventral vessels as an entry site to the CNS. Indeed,
a depletion of CD4+ T cells including pathogenic ones from EAE‐recovered mice abrogated
the clinical symptoms of EAE relapse (i.e. paralysis), but the accumulation of MHC class II
high monocytes around the L5 ventral vessels remained intact. These results suggested that
the activated monocyte accumulation is an upstream event relative to pathogenic CD4+ T‐cell
invasion and required for EAE relapse induced by pain sensation [13].
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The sympathetic nerve activation caused by pain appeared to be relatively systemic compared
with that via the sensory pathway, since the expression levels of neural activation marker c‐
Fos increased in certain nerve cells in sympathetic ganglions at all spinal levels investigated,
which is in contrast to the gravity‐mediated gateway reflex in which the L5 sympathetic
ganglion alone showed the highest expression of c‐Fos. However, the pain‐mediated gateway
reflex affects blood vessels at the ventral sides of the L5 spinal cord. Why does the pain‐
mediated gateway reflex influence the L5 level alone, similar to the gravity‐mediated gateway
reflex? We assume that this property is related to the fact that the L5 cord is the first lesion in
the transfer EAE model. Even at the remission phase of transfer EAE, MHC class II high
monocytes that have infiltrated in the CNS during the initial episode remained mostly in the
L5 spinal cord despite the disappearance of clinical symptoms [13]. Otherwise, gravity‐
mediated neural inputs might make the L5 environment different from other CNS regions.
Whichever the explanation, we found that pain induction similarly triggers sympathetic neural
activation to some neuron cells of every spinal level, but the L5 spinal cord responded
strongest, most likely due to an abundance of activated monocytes.
It is known that pain‐sensing neurons activate sympathetic neurons at least partially via the
anterior cingulate cortex (ACC) in the somatosensory area of the brain [49, 50]. Blockade of
this sensory‐sympathetic connection by the injection of an N‐methyl‐D‐aspartate (NMDA)
receptor antagonist at the ACC suppressed the accumulation of MHC class II high monocytes
at the L5 ventral vessels even after pain induction, and conversely, injection of an NMDA
agonist at the ACC induced the accumulation of these cells without pain stimulation in EAE‐
recovered mice. These results clearly suggest that the sensory‐sympathetic connection at the
ACC is involved in pain‐mediated EAE relapse. Thus, we showed a third pain‐mediated
gateway reflex where neural signals travel from a TRPV1 and Nav1.8‐dependent sensory
circuit to sympathetic neurons via the ACC, reaching the dorsal vessels of the spinal cords [13]
(Figure 3).
The study of the pain‐mediated gateway reflex also highlights the importance of MHC class
II high monocytes for EAE relapse. Parabiosis experiments, in which two different congenically
marked mice are joined together surgically to share blood circulation, revealed that MHC class
II high monocytes that accumulated at the L5 ventral vessels were derived from the peripheral
blood stream during the first EAE development and stayed in the CNS, but not from resident
microglia in the CNS [13]. These infiltrated MHC class II high monocytes survive in the CNS
during the remission phase and play a pathogenic role upon relapse when the mice have a
pain sensation. Therefore, in addition to controlling neural pathways and/or molecular
machinery of the gateway reflexes, MHC class II high monocytes could also be a potential
cellular target for treatment of relapse‐remitting MS and progressive‐relapsing MS.
6. Other gateway reflexes
In addition to the sensory perceptions described above, including gravity‐, electric stimula‐
tion‐, and pain‐mediated stimuli, neural excitations occur in response to emotional alterations
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and physical/mental stresses. These physiological events too are often associated with MS
symptoms [51]. Worsening of the clinical symptoms of neurological diseases including MS
when the body is exposed to high ambient temperatures, called Uhthoff's phenomenon, is
another well‐known example [52]. It is also known that stress burdens are associated with
activation of the sympathetic nervous system, such as increased noradrenaline levels in the
peripheral blood. Despite these correlations, a mechanical link between stress and disease
development remains elusive. Neuronal activations, noradrenaline surge, and disease
development are fundamental of the gateway reflex. Stress‐induced neural signals traveling
to the CNS might modulate specific blood vessels depending on stress type, opening or closing
a gateway for immune cells in the CNS. To examine this possibility, we have been testing the
effects of various stresses on the pathogenesis of EAE. Although restraint stress and forced
swim stress did not provoke EAE relapse [13], some stresses were found to worsen the clinical
symptoms, whereas another stress prevented EAE development. These phenomena represent
the fourth and fifth examples of the gateway reflex. The effects of good stress, or eustress, have
also been reported in cancer models, in which tumor growth is delayed when mice are reared
under an enriched environment with running wheels, tunnels, etc. in a larger cage [53, 54]. We
suggest it may be possible to prevent diseases if stimulating the appropriate neurons can
trigger a good gateway reflex.
Kevin Tracey and his colleagues have reported that activation of the vagus nerves, which
mainly consist of parasympathetic nerves, leads to the suppression of systemic inflammation
during septic shock in mice. This neural reflex is specifically called the “inflammatory reflex.”
In this context, lipopolysaccharide treatment in mice leads to norepinephrine release in the
spleen via vagus and splenic nerves. A subset of T cells that receive norepinephrine signaling
produces acetylcholine, which acts on macrophages to suppress the lipopolysaccharide‐
induced expression of inflammatory mediators such as TNFα [55], thus acting as a negative
feedback system for excessive inflammatory reactions such as septic shock. It is also reported
that electro‐acupuncture in mice at the ST36 Zusanli acupoint, which is located close to the
common peroneal and tibial branches of the sciatic nerve, or directly to the sciatic nerve
prevents a sepsis model through vagal activation and dopamine production [56]. A similar
strategy may generate the gateway reflex in humans.
7. Inflammation amplifier
As described above, regional sensory neural activations transmit neural signals to sympathetic
neurons, which then secrete norepinephrine at the target blood vessels to establish a gateway
and recruit immune cells. Because chemokines have a critical role in immune cell recruitment,
we hypothesized that machinery responsible for the production of chemokines could act as an
interface between neural signals and immune reactions. Indeed, we discovered the inflam‐
mation amplifier, which is a local chemokine inducer. In this section, we describe the inflam‐
mation amplifier as a molecular mechanism for neuro‐immune interactions in blood vessels.
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Figure 4. Inflammation amplifier. Simultaneous activation of the transcription factors NF‐κB and STATs creates a syn‐
ergistic effect on the production of inflammation mediators, such as chemokines, growth factors, and IL‐6, in nonim‐
mune cells, such as vascular endothelial cells and fibroblasts. Factors activating NF‐κB and STATs are various and
include IL‐6, TNFα, and IL‐17. IL‐6 is expected to act on nonimmune cells to form a positive feedback loop that ampli‐
fies this synergistic effect. Massive chemokine and growth factor production by this mechanism, called the inflamma‐
tion amplifier, plays a central role in the pathogenesis of many inflammatory diseases and disorders.
To establish an IL‐6‐dependent autoimmune mouse model, we previously generated a knock‐
in mouse strain called F759 mice, which lacks the SOCS3 binding site of the IL‐6 signal
transducer, gp130, thereby inhibiting SOCS3‐dependent negative signaling and excessive
STAT3 activation [57]. Accordingly, F759 mice developed spontaneous rheumatoid arthritis‐
like joint disease and autoantibody production [58], which is consistent with the high levels of
IL‐6 and clinical success of its signaling blockade in rheumatoid arthritis patients [59, 60]. Using
these autoimmune‐prone F759 mice, we performed mechanistic analyses for the pathogenesis
of their autoimmunity and found that IL‐6 signaling in nonimmune cells, such as vascular
endothelial cells and fibroblasts, rather than immune cells, is important for the exaggerated
inflammation [61, 62]. Mechanistically, coactivation of the transcription factors NF‐κB and
STATs in nonimmune cells led to a synergistic production of inflammatory agents, including
chemokines and growth factors, compared with NF‐κB or STAT activation alone (Figure 4).
Factors that activate NF‐κB and STATs and therefore trigger the inflammation amplifier
include IL‐17A, TNFα, IL‐22, IL‐6, and IFNγ. Furthermore, neurotransmitters, including
The Gateway Reflex, a Novel Neuro‐immune Interaction, is Critical for the Development of Mouse Multiple Sclerosis
(MS) Models
http://dx.doi.org/10.5772/62938
41
norepinephrine and several growth factors, augment the amplifier by enhancing NF‐κB
activation [12, 63]. Since chemokines can recruit immune cells and promote inflammation, we
named this synergistic mechanism in nonimmune cells the “inflammation amplifier” [64, 65].
Mice lacking gp130 or STAT3 in type 1 collagen+ cells including various nonimmune cells were
highly resistant to animal models of rheumatoid arthritis, MS, and chronic graft rejection via
suppression of the regional accumulation of immune cells [12, 13, 62, 63, 66, 67]. The inflam‐
mation amplifier is also seen in astrocytes, resulting in the development of EAE [68]. In
addition, we found evidence of the inflammation amplifier activation in human clinical
specimens, and human disease‐associated genes are highly enriched in inflammation ampli‐
fier‐related genes according to genome‐wide RNA functional screening [67]. These data
suggested that the inflammation amplifier is a critical mechanism for the development of
various inflammatory diseases via excessive expression of inflammatory chemokines and
growth factors from nonimmune cells (Figure 4).
Subsequent studies about the gateway reflex demonstrated that neural signals translate into
inflammatory signals by the inflammation amplifier in target vascular endothelial cells. In the
case of the gravity‐mediated gateway reflex, neural signals from the soleus muscles reached
the L5 dorsal vessel endothelium via sensory‐sympathetic cross talk, where norepinephrine
from the activated sympathetic neurons excessively stimulated the inflammation amplifier by
increasing NF‐κB activity to secrete various NF‐κB‐targets including chemokines. Moreover,
the L5 but not L1 dorsal vessel endothelium showed activation of STAT3. Pharmacological
inhibition of beta‐adrenergic receptors suppressed NF‐κB activation, chemokine production,
and pathogenic CD4+ T‐cell accumulation in the L5 dorsal vessels and EAE development [12].
Similarly, during the pain‐mediated gateway reflex, treatment with a beta‐adrenergic receptor
antagonist resulted in no accumulation of activated monocytes or pathogenic CD4+ T cells
around the target dorsal vessels of the L5 spinal cord. Neutralization of cytokines that activate
the inflammation amplifier such as IL‐6 and IL‐17A also suppressed the pain‐induced EAE
relapse and pathogenic CD4+ T‐cell accumulation [13]. These results indicate that the inflam‐
mation amplifier is a foundation of the immunological response induced by the gateway reflex.
8. Future directions
The CNS is an immune‐privileged site protected by the BBB, but the gateway reflex, which
can be triggered by various neural stimulations, can induce gateways for immune cells to
circumvent the BBB. So far, three kinds of gateway reflex have been identified: gravity, elec‐
tric stimulation, and pain‐induced, all of which involve sensory‐sympathetic communica‐
tion. Further study of the mechanisms driving the gateway reflex should consider the neural
network involved and whether it is present in other organs and tissues. Newly developed
imaging techniques and tools including a tissue decolorization reagent, CUBIC [69, 70], will
help elucidate the former. For the latter, it is recently reported there exists barrier architec‐
ture with similar components to the BBB in the gut endothelium, the so‐called gut‐vascular
barrier [22]. A similar system may explain how immune cells breach this barrier. Because
neuronal circuits run throughout the body, the gateway reflex could have a tremendous
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clinical benefit, as closing a specific gateway would dampen autoimmune inflammation in a
target organ without massive systemic immune suppression, while opening it in tumors
could enhance cancer immunotherapy.
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